This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Rocket Pharmaceuticals Class Action Lawsuit
Business class action lawsuit

Rocket Pharmaceuticals Class Action Lawsuit

Analysis based on 26 articles · First reported Jun 12, 2025 · Last updated Aug 05, 2025

Sentiment
-70
Attention
6
Articles
26
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Rocket Pharmaceuticals for alleged securities fraud and undisclosed clinical trial risks has led to a significant decline in its stock price. This event highlights the importance of transparency in clinical trials for biotechnology companies, potentially increasing scrutiny from investors and regulatory bodies on similar firms.

Biotechnology Legal Services
Event Summary

Rocket Pharmaceuticals is facing a class action lawsuit, led by Marc Randolph, for allegedly making misleading statements and concealing material adverse facts regarding the safety and clinical trial protocol of its RP-A501 drug. The lawsuit claims that Rocket Pharmaceuticals failed to disclose a substantive amendment to the trial's protocol, which introduced a novel immunomodulatory agent, until after a patient suffered a Serious Adverse Event, including death. The United States — Food and Drug Administration subsequently placed a clinical hold on the RP-A501 Phase 2 pivotal study. Following this news, Rocket Pharmaceuticals' stock price declined by approximately 37% in a single trading day. Law firms Levi & Korsinsky and The Gross Law Firm are notifying investors and encouraging affected shareholders to join the lawsuit, with a lead plaintiff deadline of August 11, 2025.

Key Actions
100 Rocket Pharmaceuticals made misleading statements
95 United States — Food and Drug Administration placed clinical hold Rocket Pharmaceuticals
90 Levi & Korsinsky notified investors of lawsuit
90 Rocket Pharmaceuticals announced clinical hold
85 Randolph Ho commenced class action lawsuit Rocket Pharmaceuticals
Entities Involved
stock
Rocket Pharmaceuticals
Rocket Pharmaceuticals is facing a class action lawsuit for allegedly making misleading statements and concealing material adverse facts regarding the safety and clinical trial protocol of its RP-A501 drug, leading to a significant drop in its stock price.
Importance 100.0 Sentiment -80.0
per
Marc Randolph
Marc Randolph is the plaintiff who commenced the class action lawsuit against Rocket Pharmaceuticals.
Importance 60.0 Sentiment 0.0
govactor
United States — United States District Court for the District of New Jersey
The class action lawsuit against Rocket Pharmaceuticals was commenced in the United States — United States District Court for the District of New Jersey.
Importance 50.0 Sentiment 0.0
per
Randolph Ho
Randolph Ho is the named plaintiff in the class action lawsuit against Rocket Pharmaceuticals.
Importance 10.0 Sentiment 0.0
priv
Levi & Korsinsky
Importance 0.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
Rocket Pharmaceuticals related ↔ United States — Food and Drug Administration
Levi & Korsinsky related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.